eScholarship
metadata only
The 20S proteasome as an antiparasitic drug target; activity-based probes, structure-activity relationship and in vivo efficacy
Worldwide, there are about 1,400 pathogens that infect humans. In particular, for the neglected diseases of poverty that are caused by eukaryotic pathogens, chemotherapy often relies on a small number of antiquated drugs that can be toxic, and for which resistance is either established or a concern.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial#810295
- Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer.#295204
- YAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates#205757
- Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer#1007865
- Shared and specific molecular mechanisms of proteasome inhibitors in chemotherapy-induced peripheral neurotoxicity#288368
Record · ID 1174874
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive